Statement from Ralph G. Neas, President and CEO, GPhA on FDA Decision on Abuse-Deterrent Formulations of OxyContin

Published Online: Wednesday, April 17, 2013
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (April 17, 2013) — “We share the Agency’s goal of addressing prescription opioid abuse, and using a science-based approach to take on this complex problem. At the same time, we recognize the importance of balancing patient access to medicine with efforts to minimize abuse.

Yesterday’s decision from the FDA provides clear guidance on what is considered an abuse-deterrent formulation for OxyContin, information that GPhA and its member companies have been seeking since 2010.

Along with the draft guidance on abuse-deterrent formulations made available in January, this represents a beginning for other brand and generic manufacturers seeking to create these formulations.

We will continue to work with FDA to make progress on this front, contributing our comments to the public commentary period to hone the standards, and offering our manufacturers’ perspective.

As the science of abuse deterrence evolves, we look forward to making contributions to this new field.”

Related Articles
Pharmacists and their patients can help prevent prescription drug misuse, abuse, and diversion through a new educational tool launched by the Alliance for Balanced Pain Management (AfBPM).
All health care professionals acknowledge that prescription pain pill abuse is a problem.
For many pharmacy organizations, the Supreme Court King v. Burwell decision upholding the Affordable Care Act’s tax subsidies fended off potential confusion for patients concerning health insurance.
The FDA approved a 2.9-mg/0.71-mg dosage strength of Orexo’s sublingual buprenorphine/naloxone (Zubsolv).
Latest Issues
$auto_registration$